Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Trillium Therapeutics logo

About Trillium Therapeutics Stock (NASDAQ:TRIL)

Advanced Chart

Key Stats

Today's Range
$18.44
$18.44
50-Day Range
$17.50
$18.44
52-Week Range
$5.80
$20.96
Volume
8 shs
Average Volume
1.87 million shs
Market Capitalization
$1.94 billion
P/E Ratio
29.74
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Leukemia Therapeutics Global Market Report 2023
See More Headlines

TRIL Stock Analysis - Frequently Asked Questions

Trillium Therapeutics Inc. (NASDAQ:TRIL) released its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), CannaPharmaRX (CPMD), FuelCell Energy (FCEL), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/18/2021
Today
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRIL
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Trailing P/E Ratio
29.74
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,350,000.00
Pretax Margin
-113,720.92%

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Sales
12,907.39
Price / Cash Flow
N/A
Book Value
$2.56 per share
Price / Book
7.20

Miscellaneous

Free Float
95,440,000
Market Cap
$1.94 billion
Optionable
Optionable
Beta
2.08
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:TRIL) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners